IGF1-LR3 (1mg)

IGF-1 LR3 is a modified version of insulin-like growth factor 1 with an extended half-life. The LR3 modification involves substitution of Arg for Glu at position 3 and an N-terminal extension of 13 amino acids, significantly reducing binding to IGF-binding proteins. This results in enhanced bioavailability and potency for growth and anabolic research. It is classified under the Growth Peptides research category and is studied in the following areas: Muscle Growth, Cell Proliferation, Anabolic Pathways, Recovery.

Our IGF1-LR3 (1mg) is tested at 99%+ purity via third-party HPLC analysis. Every order ships with a Certificate of Analysis (COA) documenting purity, identity, and endotoxin levels.

IGF1-LR3 (1mg) should be stored at -20°C. It is supplied as a lyophilized powder and is soluble in 0.1m acetic acid.

IGF-1 receptor agonist with reduced IGF-binding protein affinity; activates PI3K/Akt and MAPK/ERK pathways promoting cell proliferation and protein synthesis

IGF1-LR3 (1mg) has a molecular weight of 9111.4 g/mol. Its amino acid sequence is: Modified IGF-1 with N-terminal 13aa extension + Arg3 substitution.

Yes. Every batch of IGF1-LR3 (1mg) is third-party tested and ships with a full Certificate of Analysis (COA) documenting HPLC purity, mass spectrometry identity confirmation, and endotoxin testing results.

20-30 hours (extended vs. native IGF-1 due to reduced IGFBP binding)

In published research, IGF1-LR3 (1mg) has been administered via subcutaneous injection, intramuscular injection. All use is for laboratory research purposes only.